Martin Bigler
Martin Bigler
SAKK Coordinating Center
Verified email at sakk.ch
Title
Cited by
Cited by
Year
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2 …
C Rochlitz, M Bigler, R von Moos, J Bernhard, K Matter-Walstra, A Wicki, ...
BMC cancer 16 (1), 1-8, 2016
252016
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, ...
BMC cancer 17 (1), 265, 2017
142017
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with …
C Rochlitz, R von Moos, M Bigler, K Zaman, S Anchisi, M Küng, KJ Na, ...
Journal of Clinical Oncology 32 (15_suppl), 518-518, 2014
142014
Clinical outcome after rectal replacement with side-to-end, colon-J-pouch, or straight colorectal anastomosis following total mesorectal excision: a Swiss prospective …
WR Marti, G Curti, H Wehrli, F Grieder, M Graf, B Gloor, M Zuber, ...
Annals of surgery 269 (5), 827-835, 2019
122019
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with …
B Drexler, JR Passweg, A Tzankov, M Bigler, APA Theocharides, ...
Haematologica 104 (4), 710-716, 2019
112019
External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26
E Herrmann, D Naehrig, M Sassowsky, M Bigler, J Buijsen, I Ciernik, ...
Radiation oncology 12 (1), 1-9, 2017
52017
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
M Zweifel, B Thürlimann, S Riniker, P Weder, R von Moos, O Pagani, ...
Endocrine connections 6 (7), 549-556, 2017
52017
Effects of the sympathicomimetic agonist mirabegron on disease course, mutant allele burden, marrow fibrosis, and nestin positive stem cell niche in patients with JAK2-mutated …
B Drexler, J Passweg, M Bigler, APA Theocharides, N Cantoni, P Keller, ...
Blood, The Journal of the American Society of Hematology 128 (22), 3108-3108, 2016
52016
NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma
B Jeker, U Novak, BM Taleghani, GM Baerlocher, K Seipel, BU Mueller, ...
Bone marrow transplantation 53 (2), 175-179, 2018
42018
Quality of life after total mesorectal excision and rectal replacement: Comparing side-to-end, colon J-pouch and straight colorectal reconstruction in a randomized, phase III …
K Ribi, WR Marti, J Bernhard, F Grieder, M Graf, B Gloor, G Curti, M Zuber, ...
Annals of surgical oncology 26 (11), 3568-3576, 2019
22019
Abstract P5-14-05: Phase 1 evaluation of the androgen receptor modulator CR1447 in patients with advanced breast cancer (SAKK 21/12)
W Schoenfeld, M Zweifel, B Thuerlimann, S Riniker, P Weder, R von Moos, ...
Cancer Research 76 (4 Supplement), P5-14-05-P5-14-05, 2016
22016
Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2 …
K Matter-Walstra, M Bigler, M Schwenkglenks, D Bärtschi, J Brechbühl, ...
SABCS. San Antonio USA, 2014
22014
1971 A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10)
R Jaggi, Z Varga, M Bigler, V Bize, MB Eduardo, S Berardi, F Chiesa, ...
European Journal of Cancer 51, S324, 2015
12015
1943 Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10)
BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, ...
European Journal of Cancer 51, S313, 2015
12015
External Beam Radiation Therapy for Unresectable Hepatocellular Carcinoma: An International Multicenter Phase I Trial, SAKK 77/07
E Herrmann, D Naehrig, J Buijsen, IF Ciernik, DR Zwahlen, AF Pellanda, ...
International Journal of Radiation Oncology• Biology• Physics 93 (3), E152, 2015
2015
Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in …
KW Matter-Walstra, M Bigler, M Schwenkglenks, D Bertschi, J Brechbühl, ...
Cancer Research 75 (9 Supplement), P1-10-06-P1-10-06, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–16